Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Breaking down barriers to foster new Cyclodextrin-based applications for healthcare by implementing sustainable design principles

Descripción del proyecto

Un gran avance en el uso de ciclodextrinas en farmacéutica

Las ciclodextrinas (CD) son un excipiente prometedor para su uso en formulaciones de fármacos y vacunas que, hace poco, han suscitado una gran atención por parte de la industria farmacéutica. Este excipiente está experimentando importantes innovaciones, con la introducción de nuevos sistemas basados en CD y aplicaciones terapéuticas. Por desgracia, la falta de comunicación y los malentendidos entre la industria privada y la comunidad científica e investigadora han obstaculizado el progreso de la utilización de CD. En el proyecto Bicyclos, financiado con fondos europeos, se pretende resolver estos problemas reuniendo a un equipo de especialistas y expertos, que formará a nuevos investigadores y, además, llevará a cabo investigaciones sobre aplicaciones y desarrollos novedosos de CD. En último término, el equipo del proyecto colaborará con un consorcio formado por once socios a fin de promover la introducción y difusión del uso de CD.

Objetivo

Cyclodextrins (CD) have already gained several market applications as excipients in drug and vaccine formulations. They are very appealing platforms for the development of therapeutic applications and new CD-based systems are continuously proposed. In this frame easily prepared CD polymers frequently outstand the performance of the corresponding CD monomers. Nevertheless, application of new CDs as drug or delivery system in the clinics does not take off in spite of their most promising features. This is mainly due to a lack in transfer of knowledge between the academic world and the private sector focusing on CD for biomedical applications. The consortium formed by a multidisciplinary team, all with interest in CD and nanomedicines, accepts the challenge to bring CD-based systems closer to clinical application. To reach this goal an intense secondment scheme for young and experienced researchers is envisaged with activities that are all contributing to the scientific pursuit of CD progress. Activities focus on the design of sustainable syntheses of new CD, full characterization of new functionalized CD, the preparation of CD delivery systems for therapeutics and the study of the biological behavior of the CD-based nanomedicines in 2D and 3D models. The teams will embrace, already from the design stage, the production standards affording compliance with GMP for medicine development and prefer strategic approaches in line with the EU 2030 Agenda for Sustainable Development. The consortium features 11 partners with 4 coming from the private sector. Two of them hold concrete interest in the exploitation of research results as their core business focuses on CD for biomedical applications. This intersectoral and interdisciplinary team will foster new applications of CD-based systems as drugs, delivery systems or sensors and participating staff will enrich their profile with scientific and soft skills that are easily transferred to other research topics or sectors.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.

Para utilizar esta función, debe iniciar sesión o registrarse

Coordinador

CONSIGLIO NAZIONALE DELLE RICERCHE
Aportación neta de la UEn
€ 184 000,00
Dirección
PIAZZALE ALDO MORO 7
00185 Roma
Italia

Ver en el mapa

Región
Centro (IT) Lazio Roma
Tipo de actividad
Research Organisations
Enlaces
Coste total
Sin datos

Participantes (8)

Socios (2)